Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 known ✓ | P31213 | 9/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 16/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | HSD3B1 | P14060 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finasteride SCHEMBL1560981 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5148287 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL11909 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5509 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL13575812 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL3982016 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22032590 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969513 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245549-A1 | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| US-5084574-A | Reacting a 3-oxo-4-azasteroid with a silyating agent and quinone to form a double bond at the #1 ring position | MERCK & CO., INC. (US) | 1992-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245549-A1 | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer | KDR, FLT4, FLT1 | SRD5A2 3493/4885SRD5A1 2965/4885LMNA 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.